Skip to main content

A Study to Compare the Safety and Efficacy of Dysport® and Botox® in Adults With Upper Limb Spasticity.

Completed · Phase 4 · NCT04936542

Conditions: Upper Limb Spasticity

At a glance

Research payments reported, 2025
$1.1M
U.S. investigators named
49
Sites paid
51
Planned or actual enrollment
464

About the trial

Sponsor
Ipsen
Tested
AboBoNT-A (biological), OnaBoNT-A (biological)
Dates
Started 2021-06-23; completion 2025-08-26
Results posted
Yes

This study is aiming to demonstrate the non-inferiority of AbobotulinumtoxinA (aboBoNT-A) versus OnabotulinumtoxinA (onaBoNT-A) as the primary safety endpoint, and the superiority of aboBoNT-A over onaBoNT-A with respect to duration of response as the key secondary efficacy endpoint when used at optimal doses according to approved prescribing information of each product.

From ClinicalTrials.gov, last updated 2026-07-09. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Ipsen Pharma Sas reported $1.1M in research payments for this study in 2025 (1,102 payments).

Products named: Dysport

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.